Department of Allergy, Kaiser Permanente Medical Center, San Diego, CA 92111, USA.
J Allergy Clin Immunol. 2011 Jul;128(1):44-49.e1. doi: 10.1016/j.jaci.2010.12.1112. Epub 2011 Feb 12.
The Asthma Impact Survey (AIS-6) is a brief disease-specific quality-of-life instrument with limited published validation data.
To obtain additional validation data and psychometric properties of the AIS-6.
In November, 2007, patients with persistent asthma were mailed a survey that included the AIS-6, the mini-Asthma Quality of Life Questionnaire (mAQLQ), and the Asthma Control Test (ACT). Follow-up surveys were sent in April, July, and October 2008. Year 2008 exacerbations and short-acting β-agonist (SABA) dispensings were captured from administrative data.
A total of 2680 patients had complete baseline survey data. Criterion validity was demonstrated by the strong correlations of the AIS-6 with the mAQLQ (r = -0.84 to -0.86); construct validity by significant relationships (P < .0001) of the AIS-6 with mAQLQ domain scores, ACT score, and history of exacerbations; and predictive validity by significant relationships (P < .0001) between AIS-6 scores at the end of 2007 and year 2008 exacerbations and high SABA dispensings. Responsiveness was demonstrated by significant (P < .0001) correlations (r = -0.39 to -0.58) between changes in AIS-6 scores and changes in mAQLQ and ACT scores over time. A preliminary minimally important difference (MID) in AIS-6 was estimated to be 4 by using the mAQLQ MID as an anchor. Excellent internal consistency (α = 0.94) and test-retest reliability (intraclass correlation coefficient = 0.86-0.91) were also demonstrated.
The AIS-6 demonstrated good psychometric properties in a large independent sample and could be used to assess asthma-specific quality of life in clinical practice and clinical research.
哮喘影响调查(AIS-6)是一种简短的疾病特异性生活质量工具,其验证数据有限。
获得 AIS-6 的额外验证数据和心理测量特性。
2007 年 11 月,向持续性哮喘患者邮寄了一份调查问卷,其中包括 AIS-6、迷你哮喘生活质量问卷(mAQLQ)和哮喘控制测试(ACT)。2008 年 4 月、7 月和 10 月还寄发了后续调查问卷。从行政数据中获取 2008 年的哮喘加重和短效β-激动剂(SABA)的配药情况。
共有 2680 名患者完成了基线调查。AIS-6 与 mAQLQ 有很强的相关性(r = -0.84 到 -0.86),这表明其具有标准效度;AIS-6 与 mAQLQ 各领域评分、ACT 评分和哮喘加重史有显著关系(P <.0001),这表明其具有结构效度;2007 年底和 2008 年 AIS-6 评分与哮喘加重和 SABA 高剂量配药之间有显著关系(P <.0001),这表明其具有预测效度。AIS-6 评分随时间的变化与 mAQLQ 和 ACT 评分的变化有显著相关性(r = -0.39 到 -0.58),这表明其具有反应性。使用 mAQLQ 的 MID 作为参考,估计 AIS-6 的最小有意义差异(MID)为 4。还表现出了极好的内部一致性(α = 0.94)和测试-重测可靠性(组内相关系数 = 0.86-0.91)。
AIS-6 在大型独立样本中表现出良好的心理测量特性,可用于评估临床实践和临床研究中的哮喘特异性生活质量。